On May 25, 2023 Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, reported that preclinical data for its oncogenic driver program targeting KRAS G12V, AFNT–211, will be presented at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, held in Chicago, June 2-6 (Press release, Affini-T Therapeutics, MAY 25, 2023, View Source [SID1234632121]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to present novel preclinical data from our cell therapy targeting KRAS G12V, highlighting the robust stemness properties of our cell product as a key aspect of its comprehensive characterization. These findings establish a solid research foundation and support our ongoing effort to advance the program as a potential paradigm-shifting treatment for solid tumors," said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. "Along with our collaborators, we will continue to push forward treatments targeting oncogenic driver mutations and look forward to presenting these findings at ASCO (Free ASCO Whitepaper) in Chicago."
Poster presentation details are as follows:
Developmental Therapeutics—Immunotherapy, Hall A, Abstract: 2543, Poster Board: 385, June 3 at 8 am CT / 9 am ET: AFNT-211: A FAS-41BB–enhanced TCR-T cell therapy with stem-like properties targeting KRAS G12V-expressing solid tumors – Presenting Authors: Thomas Schmitt, Ph.D., Fred Hutchinson Cancer Center and Scientific Co-Founder, Affini-T Therapeutics and Hue Lam, Ph.D., Vice President, Preclinical Development, Affini-T Therapeutics
"With the THRIVE T cell manufacturing platform, we can generate high yields of drug product exhibiting naïve and central memory phenotypes, enhancing the activity of this therapy," said Kim Nguyen, Ph.D., Chief Technical Officer, Affini-T Therapeutics. "Our IND-enabling studies have demonstrated potent and specific pharmacological action with a rigorous toxicology profile that support the advancement of the AFNT-211 program to the clinic."